RETA
RETA (Triple-Pathway Metabolic Receptor Agonist)
At a Glance
Molecular Properties
Overview
Compound Description
RETA is a synthetic 39-amino-acid peptide rationally designed to simultaneously engage three G-protein-coupled receptors central to metabolic homeostasis: the glucose-dependent insulinotropic polypeptide (GIP) receptor, a second incretin receptor, and the glucagon receptor. The backbone is primarily built on a GIP receptor agonist scaffold, which was then systematically modified to introduce cross-reactivity at the second incretin and glucagon receptors. It is supplied as a characterized reference compound for in-vitro receptor-pharmacology and structural research, and is not for human or animal use.
Mechanism of Action
Research-Identified Pathways
RETA's triple-receptor engagement creates complementary metabolic effects through three distinct but overlapping signaling pathways. GIP receptor agonism potentiates glucose-dependent insulin secretion and influences adipose tissue lipid handling. Activation of the second incretin receptor suppresses glucagon secretion, slows gastric emptying, and modulates appetite-regulating circuits in the hypothalamus.
The glucagon receptor component, unique to the triple-agonist approach, stimulates hepatic energy expenditure through glycogenolysis and gluconeogenesis upregulation, fatty acid oxidation, and thermogenesis. Structural studies using cryo-EM have revealed the binding conformations at all three receptors, providing molecular-level insight into the peptide's poly-pharmacology.
Key Research Findings
Published Study Highlights
- Engineered to engage three metabolic receptors: the GIP receptor, a second incretin receptor, and the glucagon receptor
- Cryo-EM structural studies have resolved the ligand binding conformations at all three target receptors
- Receptor-pharmacology work characterizes relative agonist potency and signaling bias at each of the three receptors
- Built on a GIP receptor agonist scaffold subsequently modified to introduce cross-reactivity at the other two receptors
- Used as an analytical standard in LC-MS and HPLC characterization of multi-receptor peptide agonists
Areas of Research Interest
Why Researchers Are Investigating This Compound
This compound has attracted significant research attention in the following areas. These represent active fields of scientific inquiry, not validated therapeutic claims. No medical benefits are stated or implied.
- Poly-pharmacology research: studied as a model for multi-target ligand design across a receptor family
- Structural biology: cryo-EM work resolving the three ligand-receptor interfaces is an area of active investigation
- Receptor-selectivity studies: used to probe relative agonist potency across the glucagon and incretin receptor family
- Analytical method development: employed as a reference standard in LC-MS/MS characterization of complex peptide agonists
Published Research
Peer-Reviewed References
- Wang X, Cheng L, Liu Y, et al. "Structural insights into the triple agonism at three metabolic receptors manifested by RETA." Cell Discovery (2024). doi:10.1038/s41421-024-00700-4
Research Use Only
The information presented on this page is compiled from peer-reviewed scientific literature and is provided solely for educational and research purposes. This compound is intended exclusively for laboratory and scientific research use. It is not a drug, pharmaceutical, or dietary supplement. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. No claims of therapeutic efficacy are made or implied.
Researchers are advised to consult the original published studies referenced above for complete methodological details, study limitations, and the authors' own conclusions. Atlas Peptide Research does not endorse any specific research application and provides this information as a reference resource only.
Interested in RETA?
View this compound in our shop to see available sizes, certificates of analysis, and current pricing.
View in Shop